KOLINPHARMA® has achieved the first patent for Doltendix®

KOLINPHARMA® has achieved the first patent for Doltendix®, the product was launched in June 2021, and actually, the number of patents has risen to 45 patents.

The department of R&D has developed Doltendix®, it is a food supplement formulated for the well–being of the tendons, based on bioactive peptides from collagen, astaxanthin, trans-resveratrol, and vitamin C.

Rita Paola Petrelli, President of Kolinpharma has commented: “After less one year from the launch of Doltendix®, we are proud to proclaim the concession of the patent in Italy, the result of the hard-working and profitable of the R&D.

We are aware of the value of our formulations, we are interested in requesting the demand of other patents foreign, according to our strategic line and we continue to invest in innovation of our product. 
 

KOLINPHARMA® has achieved the first patent for Doltendix®, the product was launched in June 2021, and actually, the number of patents has risen to 45 patents.

The department of R&D has developed Doltendix®, it is a food supplement formulated for the well–being of the tendons, based on bioactive peptides from collagen, astaxanthin, trans-resveratrol, and vitamin C.

Rita Paola Petrelli, President of Kolinpharma has commented: “After less one year from the launch of Doltendix®, we are proud to proclaim the concession of the patent in Italy, the result of the hard-working and profitable of the R&D.

We are aware of the value of our formulations, we are interested in requesting the demand of other patents foreign, according to our strategic line and we continue to invest in innovation of our product.